Invizius inks Series A

Invizius Limited, a developer of treatments to suppress unwanted innate immune responses, has secured 5.3 million pounds in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this